1991 Volume 39 Issue Supplement3 Pages 372-384
We studied a newly developed carbapenem, panipenem/betamipron (PAPM/BP), and obtained the following results.
1) Clinical pharmacological studies of PAPM/BP were conducted in 16 patients with renal dysfunction. The drug was injected intravenously, in a dose of 0.5g/0.5g by drip infusion for 60 minutes, and serum and urine levels of panipenem (PAPM) and betamipron (BP) were determined by bioassay and high-performance liquid chromatography (HPLC). The patients were classified according to creatinine clearance (Ccr) values into group I (n=5, Ccr ≥ 60ml/min), group II (n=5, 30 ≤ Ccr≤60ml/min), group III (n=6, Ccr≤30ml/min). The peak of serum levels of PAPM and BP did not differ greatly among the three groups. T1/2β of PAPM was 1.42 hour in the group I, 1.78 hour in the group II, and 3.94 hour in the group III, and that of BP was 0.71 hour in I, 1.31 hour in II, and 5.77 hour in III. Thus, in the patients with severe renal dysfunction, serum concentration decreased more slowly than in those with moderate renal dysfunction. Urinary elimination rate of PAPM was 35.46% in the group I, 28.04% in the group II, and 11.86% in the group III, indicating the renal function-related decrease in the elimination rate.
2) PAPM/BP was used to treat 33 patients with respiratory tract infections. Clinical response was excellent in 1, good in 28, fair in 1, and poor in 3 patients. Adverse reactions were elevations of GOT and GPT in 2, elevations of GOT in 2, an elevation of AL-P, γ-GTP and LAP in 1, an elevation of GOT and eosinophilia in 1, an elevation of AL-P and a decline in prothrombin activity in 1, and an elevation of AL-P and LDH in 1. However, these findings were slight and no severe side effects caused by the drug were observed.
